Plain-English translation of NCT06136559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called against two standard blood cancer treatments ( or ) in people who have just been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma and have never had treatment before. The study wants to see if the new medication works as well as or better than the existing options, and whether it helps people live longer without their cancer getting worse.
Current treatments for this type of blood cancer work well for many patients, but doctors are always looking for options that might work better or cause fewer side effects. This trial aims to find out whether this medication could be a better choice for patients starting treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either the new medication or one of the two existing medications by mouth every day. You will continue taking your assigned medication until your cancer stops responding to it, you experience unacceptable side effects, or your doctor decides you should stop for another reason. Throughout the study, you will have regular visits with your doctor for check-ups, blood tests, and imaging scans to see how well the medication is working.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States